Cognito Therapeutics, Ochsner Health Partner on Alzheimer’s Care Innovation Hub
Event summary
- Cognito Therapeutics and Ochsner Health launched the Brain Health Collaboratory to advance Alzheimer’s care models in the Gulf South.
- The initiative combines Cognito’s Spectris technology with Ochsner’s clinical network to serve urban and rural communities.
- A new 132,000-square-foot neuroscience facility at Ochsner Medical Center is set to open in late 2026.
- The partnership aims to develop a Brain Health Index to track cognitive health and treatment response.
- Spectris, Cognito’s investigational at-home neuroprotective device, received FDA Breakthrough Device Designation in 2021.
The big picture
This partnership aligns with the growing trend of health systems adopting neurotechnology to address the rising burden of Alzheimer’s disease. By combining Cognito’s Spectris with Ochsner’s expansive network, the initiative aims to generate real-world evidence that could reshape care delivery models. The collaboration also highlights the increasing focus on value-based care, particularly for dual-eligible Medicare and Medicaid populations.
What we're watching
- Technology Integration
- How Cognito’s Spectris will be integrated into Ochsner’s clinical care models for Alzheimer’s patients.
- Regulatory Pathways
- Whether the collaboration will accelerate FDA approval or payer coverage for non-invasive neuromodulation therapies.
- Market Expansion
- The pace at which Cognito can replicate this model with other health systems to broaden patient access.
Related topics